# Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

> **NCT02083679** · PHASE1 · TERMINATED · sponsor: **EMD Serono** · enrollment: 15 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine
- **DRUG:** Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed
- **DRUG:** Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
- **DRUG:** Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel

## Key facts

- **NCT ID:** NCT02083679
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor the return rights of the compound to the collaboration partner for further clinical development
- **Last updated:** 2016-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083679, "Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02083679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*